Hutchison China MediTechの資本の返還
Hutchison China MediTechの資本の返還は何ですか。
Hutchison China MediTech Ltd.の資本の返還は-5.61%です。
資本の返還の定義は何ですか。
株主資本利益率は、株主資本の簿価との関係で事業の収益性の尺度です。これは、会計年度純利益を株主資本合計で除算することによって計算されます。
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
LSEのセクタHealth Careにおける資本の返還の企業と比べるHutchison China MediTech
Hutchison China MediTechは何をしますか。
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company develops HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.
Hutchison China MediTechと類似の資本の返還
- Citi Trends Incの資本の返還は-5.64%です。
- Royal Vopak NVの資本の返還は-5.64%です。
- Royal Vopak NVの資本の返還は-5.64%です。
- Vocera Communication Incの資本の返還は-5.63%です。
- BlackRock Floating Rate Income Trustの資本の返還は-5.63%です。
- Anjani Portland Cementの資本の返還は-5.63%です。
- Hutchison China MediTechの資本の返還は-5.61%です。
- Oxford Technology VCT 3の資本の返還は-5.61%です。
- Craft Brew Allianceの資本の返還は-5.61%です。
- Silk Road Servicesの資本の返還は-5.60%です。
- Montello Resourcesの資本の返還は-5.60%です。
- Golden Independence Miningの資本の返還は-5.59%です。
- Lai Sun Garment (International)の資本の返還は-5.58%です。